- Trials with a EudraCT protocol (24)
 - Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
 
		
	   		
	   		    
                    
                   	
                   	    24 result(s) found for: Cold ischemia.
                    
                
			
   			
		
		Displaying page 1 of 2.
	
	
	| EudraCT Number: 2017-001581-20 | Sponsor Protocol Number: IRRB/72/14 | Start Date*: 2018-02-08 | |||||||||||||||||||||
| Sponsor Name:ISTITUTO MEDITERRANEO PER I TRAPIANTI E TERAPIE AD ALTA SPECIALIZZAZIONE - ISMETT | |||||||||||||||||||||||
| Full Title: THE ADDITION OF SIMVASTATIN ADMINISTRATION TO COLD STORAGE SOLUTION OF EXPLANTED WHOLE LIVER GRAFTS FOR FACING ISCHEMIA/REPERFUSION INJURY IN AN AREA WITH LOW RATE OF DECEASED DONATION. A MONOCENT... | |||||||||||||||||||||||
| Medical condition: ISCHEMIC REPERFUSION INJURY AFTER LIVER TRANSPLANTATION: HEPATIC ISCHEMIA AND REPERFUSION INJURY REPRESENTS THE MAIN UNDERLYING MECHANISM FOR GRAFT DYSFUNCTION, AND FAILURE, POST-TRANSPLANTATION. H... | |||||||||||||||||||||||
					
						
							
  | 
			|||||||||||||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: IT (Completed) | |||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||
| EudraCT Number: 2006-002938-38 | Sponsor Protocol Number: MHH – EPONTX – 01/06 | Start Date*: 2006-11-17 | 
| Sponsor Name:Hannover Medical School | ||
| Full Title: EFFECT OF ERYTHROPOIETIN ON RENAL FUNCTION AFTER KIDNEY TRANSPLANTATION | ||
| Medical condition: We will investigate the effect of recombinant human erythropoietin (rHuEPO) on ischemia-reperfusion injury in patients with terminal renal failure undergoing cadaveric kidney transplantation. In th... | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: DE (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2005-000295-41 | Sponsor Protocol Number: Ro-002/05 | Start Date*: 2006-05-29 | 
| Sponsor Name:Universität zu Köln | ||
| Full Title: Double-blind,placebo-controlled cross-over study for evaluation of the efficacy of the PDE-5-inhibitor vardenafil on the peripheral perfusion and the clinical symptomatology of patients with Raynau... | ||
| Medical condition: Raynaud´s disease (RD) is defined as episodic, painful, cold- or emotional stress-triggered vasospasms of the digital arteries and precapillary arterioles for up to 30 minutes with or without under... | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: DE (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2007-003728-39 | Sponsor Protocol Number: Euro SPK 003 | Start Date*: 2010-12-07 | 
| Sponsor Name:Centre Hospitalier Universitaire de Liège | ||
| Full Title: A EUROPEAN MULTICENTER OPEN-LABEL RANDOMIZED TRIAL TO EVALUATE THE REDUCTION OF ISCHEMIA / REPERFUSION INJURY AFTER DE NOVO SIMULTANEOUS PANCREAS/KIDNEY TRANSPLANTATION IN TYPE 1-DIABETIC PATIENTS ... | ||
| Medical condition: End-stage, C-peptide-negative, type 1-diabetic patients undergoing a first combined pancreas/kidney transplantation from a cadaver donor only will be enrolled in the study | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: BE (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2021-005723-20 | Sponsor Protocol Number: RC31/20/0445 | Start Date*: 2022-02-10 | 
| Sponsor Name:CHU de Toulouse | ||
| Full Title: Evaluation of Botulinum TOXin type A in the treatment of Buerger’s disease | ||
| Medical condition: This study assesses the feasibility and safety of treatment with botulinum toxin injection in patients with Buerger's disease | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: FR (Trial now transitioned) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2021-000099-12 | Sponsor Protocol Number: APHP180617 | Start Date*: 2021-10-12 | |||||||||||
| Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS | |||||||||||||
| Full Title: Dose-adjustment of enoxaparin by a bayesian pharmacological approach in pediatric renal transplant recipients | |||||||||||||
| Medical condition: Allograft vascular thrombosis | |||||||||||||
					
						
							
  | 
			|||||||||||||
| Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2013-002696-18 | Sponsor Protocol Number: SUN101-303 | Start Date*: 2013-12-18 | |||||||||||
| Sponsor Name:Sunovion Respiratory Development Inc. | |||||||||||||
| Full Title: A Randomized, Open-Label, Active-Controlled, Parallel-Group, Multicenter, Long-Term Safety Trial of Treatment with Nebulized SUN-101 in Patients with COPD: GOLDEN-5 (Glycopyrrolate for Obstructive ... | |||||||||||||
| Medical condition: | |||||||||||||
					
						
							
  | 
			|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: CZ (Completed) HU (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2020-000419-56 | Sponsor Protocol Number: TCD601B101 | Start Date*: 2021-03-23 | |||||||||||
| Sponsor Name:ITB-MED AB | |||||||||||||
| Full Title: A 12-month, randomized, controlled, open-label, dose escalation study evaluating safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of an anti-CD2 monoclonal antibody, TCD601 (si... | |||||||||||||
| Medical condition: renal transplantation | |||||||||||||
					
						
							
  | 
			|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: SE (Ongoing) AT (Trial now transitioned) ES (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2010-020989-20 | Sponsor Protocol Number: QRK.006 Part B | Start Date*: Information not available in EudraCT | |||||||||||
| Sponsor Name:Quark Pharmaceuticals, Inc. | |||||||||||||
| Full Title: Controlled, Randomized, Prospective, Double-Blind, Multicenter, Phase I/II, Dose-Escalation Study of the Safety, PK, and Clinical Activity of I5NP for Prophylaxis of Delayed Graft Function in Patie... | |||||||||||||
| Medical condition: I5NP is being developed for the prophylaxis of delayed graft function (DGF) in patients receiving renal transplants. The patient population of the current study will include patients undergoing dec... | |||||||||||||
					
						
							
  | 
			|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) ES (Prematurely Ended) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2021-001732-25 | Sponsor Protocol Number: PBF-680CT-06 | Start Date*: 2021-08-13 | |||||||||||
| Sponsor Name:Palobiofarma, S.L | |||||||||||||
| Full Title: A phase IIa, randomized, double blind, placebo-controlled study to assess the effect of PBF-680 in patients with moderate to severe COPD on top of standard medication. | |||||||||||||
| Medical condition: Patients with moderate to severe Chronic Obstructive Pulmonar Disease (COPD) | |||||||||||||
					
						
							
  | 
			|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: ES (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2013-000322-66 | Sponsor Protocol Number: CRAD001A2433 | Start Date*: 2013-11-07 | |||||||||||
| Sponsor Name:Novartis Pharma Services AG | |||||||||||||
| Full Title: A 24 month, multicenter, randomized, open-label safety and efficacy study of concentration-controlled everolimus with reduced calcineurin inhibitor vs mycophenolate with standard calcineurin inhibi... | |||||||||||||
| Medical condition: Adult kidney transplant recipients. | |||||||||||||
					
						
							
  | 
			|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) IT (Completed) SK (Completed) ES (Completed) PT (Completed) AT (Completed) NL (Completed) BE (Completed) GR (Completed) CZ (Completed) SI (Completed) BG (Completed) PL (Completed) HR (Completed) NO (Completed) SE (Completed) FR (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2010-021333-31 | Sponsor Protocol Number: TOP2010-LMU | Start Date*: 2011-08-23 | |||||||||||
| Sponsor Name:Klinikum der Universität München | |||||||||||||
| Full Title: Reduktion des Ischämie-Reperfusionsschadens durch ex-vivo Tacrolimus-Perfusion marginaler Organe vor Lebertransplantation (Tacrolimus-Organ-Perfusion TOP-Studie) | |||||||||||||
| Medical condition: Chonical terminal liver insufficiency | |||||||||||||
					
						
							
  | 
			|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Prematurely Ended) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2009-015456-14 | Sponsor Protocol Number: CAEB071A2214 | Start Date*: 2010-01-11 | |||||||||||
| Sponsor Name:Novartis Pharma Services AG | |||||||||||||
| Full Title: A partially blinded, prospective, randomized multicenter study evaluating efficacy, safety and tolerability of oral sotrastaurin plus standard or reduced exposure tacrolimus vs. myfortic plus tacro... | |||||||||||||
| Medical condition: Renal allograft transplantation | |||||||||||||
					
						
							
  | 
			|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: PT (Prematurely Ended) BE (Prematurely Ended) HU (Prematurely Ended) DE (Completed) SE (Prematurely Ended) NL (Prematurely Ended) DK (Completed) GB (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2017-003607-22 | Sponsor Protocol Number: CCFZ533A2201 | Start Date*: 2018-07-13 | |||||||||||
| Sponsor Name:Novartis Pharma AG | |||||||||||||
| Full Title: A partially-blinded, active-controlled, multicenter, randomized study evaluating efficacy, safety, tolerability, pharmacokinetic (PK) and pharmacodynamic (PD) of an anti-CD40 monoclonal antibody... | |||||||||||||
| Medical condition: Renal transplantation | |||||||||||||
					
						
							
  | 
			|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: SE (Completed) NL (Prematurely Ended) NO (Prematurely Ended) FR (Prematurely Ended) GB (GB - no longer in EU/EEA) DE (Prematurely Ended) ES (Prematurely Ended) CZ (Completed) BE (Prematurely Ended) HU (Prematurely Ended) SK (Prematurely Ended) LV (Prematurely Ended) LT (Prematurely Ended) IT (Prematurely Ended) HR (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2018-001037-41 | Sponsor Protocol Number: RPL554-CO-204 | Start Date*: 2018-09-04 | |||||||||||
| Sponsor Name:Verona Pharma plc | |||||||||||||
| Full Title: A PHASE II, RANDOMISED, DOUBLE BLIND, PLACEBO CONTROLLED, THREE WAY CROSSOVER STUDY TO ASSESS THE BRONCHODILATOR EFFECT OF RPL554 ADMINISTERED IN ADDITION TO OPEN LABEL TIOTROPIUM/OLODATEROL IN PAT... | |||||||||||||
| Medical condition: Chronic Obstructive Pulmonary Disease (COPD) | |||||||||||||
					
						
							
  | 
			|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2011-003795-36 | Sponsor Protocol Number: CERL080ADE27 | Start Date*: Information not available in EudraCT | |||||||||||
| Sponsor Name:Novartis Pharma GmbH | |||||||||||||
| Full Title: Multi-center, open-label, prospective, randomized, parallel group study investigating a tacrolimus Hexal® based regimen versus a Prograf® based regimen in de novo renal transplant recipients | |||||||||||||
| Medical condition: renal transplantation | |||||||||||||
					
						
							
  | 
			|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2015-003078-33 | Sponsor Protocol Number: QRK306 | Start Date*: 2016-04-13 | |||||||||||
| Sponsor Name:Quark Pharmaceuticals, Inc. | |||||||||||||
| Full Title: A Phase 3, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of QPI-1002 for Prevention of Delayed Graft Function in Recipients of a Donation After Brain Death ... | |||||||||||||
| Medical condition: QPI-1002 is being developed for the prevention of Delayed Graft Function in patients receiving renal transplants. The patient population of the current study will include patients undergoing deceas... | |||||||||||||
					
						
							
  | 
			|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: ES (Completed) CZ (Completed) BE (Completed) NL (Prematurely Ended) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2008-008339-27 | Sponsor Protocol Number: A0081107 | Start Date*: 2009-05-07 | |||||||||||
| Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY10017 | |||||||||||||
| Full Title: A 17-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTI-CENTER TRIAL OF PREGABALIN FOR THE TREATMENT OF CHRONIC CENTRAL NEUROPATHIC PAIN AFTER SPINAL CORD INJURY | |||||||||||||
| Medical condition: Chronic Central Neuropathic Pain after Spinal Cord Injury. | |||||||||||||
					
						
							
  | 
			|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: CZ (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2005-004431-21 | Sponsor Protocol Number: IBERICA | Start Date*: 2006-02-17 | 
| Sponsor Name:Fresenius Biotech GmbH | ||
| Full Title: Estudio abierto, multicéntrico, aleatorio, con el objetivo de evaluar la eficacia y la seguridad de la inmunosupresión tras un primer trasplante renal cadavérico a corazón latiente basado la utiliz... | ||
| Medical condition: Trasplante renal de donante cadavérico | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: ES (Completed) PT (Prematurely Ended) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2020-000599-38 | Sponsor Protocol Number: RC20_0007 | Start Date*: 2020-11-26 | |||||||||||
| Sponsor Name:NANTES CHU | |||||||||||||
| Full Title: A phase I/II study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of FR104, a novel antagonist pegylated anti-CD28 Fab’ antibody fragment in de novo renal trans... | |||||||||||||
| Medical condition: Kidney transplant | |||||||||||||
					
						
							
  | 
			|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
			Subscribe to this Search
To subscribe to the RSS feed for this search click here
			.
			This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
		
			
To subscribe to the RSS feed for this search click here
			.
			This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
		| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
    	Query did not match any studies.